ClinicalTrials.gg
Drug

Dabrafenib clinical trials

Also written GSK2118436 and GSK-2118436A.

Includes 9 studies of Dabrafenib mesylate.

studies test it
97
open now
17
in phase 3
9
first study started
2009

How each study uses dabrafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the dabrafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 May 2013 · TAFINLAR · NDA 202806 (FDA, Drugs@FDA; as dabrafenib mesylate)
European Union
26 Aug 2013 · Tafinlar · EMEA/H/C/002604 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Dabrafenib
69
Tafinlar
16
BRAF Inhibitor GSK2118436
13
DAB
2

Development codes

GSK2118436
31
GSK-2118436A
10
DRB436
10

In one entry with another drug

Given together, or one or the other

Dabrafenib+Trametinib
2

Studies by the year they started

97 studies that test it; most in 2014 (13)

Studies that test dabrafenib, by start year
YearStudies
20091
20104
20114
20129
201311
201413
20155
20167
20178
20187
20193
20205
20217
20222
20233
20243
20254
20261

By phase

A phase 1/2 study counts in both.

Phase 1
33
Phase 2
59
Phase 3
9
Phase 4
3
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 38 · Other 59

Novartis Pharmaceuticals (19) · GlaxoSmithKline (16) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (4) · Massachusetts General Hospital (3) · Melanoma Institute Australia (2) · Memorial Sloan Kettering Cancer Center (2) · University of California, San Francisco (2)

Often tested with

Tested in the same studies.

Trametinib (58) · Nivolumab (8) · Pembrolizumab (6) · Vemurafenib (5) · Ipilimumab (4) · Binimetinib (4) · Palbociclib (4) · Pertuzumab (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Dabrafenib is the comparator. A study of two new drugs counts under both.

  • 1Cabozantinib · ECOG-ACRIN Cancer Research Group · next primary completion Sep 2030
Reaching primary completion within a year · 9

Studies that test dabrafenib.

Studies

Open first, then newest update. How each study uses dabrafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 97

See all 97 studies that test dabrafenib →

Given beside what is tested · 31 — dabrafenib is usual care or a partner of the new treatment

Showing 20 of 31.

As the comparator · 1 — what is tested is compared with dabrafenib

Codes

What other systems call dabrafenib · ClinicalTrials.gg INT005899

  • MeSH (NLM) C561627dabrafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) QGP4HA4G1BDABRAFENIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1424911Confirmed FDA, Wikidata
  • Wikidata Q3011604dabrafenibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C82386DabrafenibOne source FDA
  • DrugBank DB08912One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.